Pharmaceuticals

Gabapentin Market 2026–2030: Emerging Trends and Forecast Opportunities

February 16, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the gabapentin market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Gabapentin Market reach by 2030 starting from 2026 levels?

The gabapentin market has experienced substantial growth in recent years. It is anticipated to expand from $3.01 billion in 2025 to $3.26 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.4%. The increase observed in the historic period can be ascribed to epilepsy treatment adoption, neuropathic pain prevalence, generic drug availability, physician prescribing patterns, and chronic disease burden.

The gabapentin market is projected to experience substantial expansion in the coming years. Its value is anticipated to reach $4.45 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. This expansion during the forecast period is attributable to factors such as an aging population, the increase in diabetic neuropathy, greater generic penetration, advancements in outpatient pain management, and the rise of telemedicine prescriptions. Key trends anticipated for this period encompass the growing application in neuropathic pain management, a surge in demand for generic formulations, the broadening of chronic pain treatment initiatives, the proliferation of oral solid dosage forms, and a rise in prescriptions for various neurological disorders.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24544&type=smp

How Is The Gabapentin Market Divided Into Segments?

The gabapentin market covered in this report is segmented –

1) By Type: Generic, Branded

2) By Dosage Form: Tablet, Capsule, Oral Solution

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By Application: Epilepsy, Neuropathic Pain, Restless Legs Syndrome, Other Applications

Subsegments:

1) By Generic: Gabapentin Immediate Release (IR), Gabapentin Extended Release (ER), Gabapentin Capsules, Gabapentin Tablets, Gabapentin Oral Solution

2) By Branded: Neurontin, Gralise, Horizant, Other Branded Formulations

Which Trends Are Expected To Influence The Gabapentin Market In The Upcoming Years?

Key players within the gabapentin market are prioritizing the development of advanced formulations, such as bioequivalent tablets, to improve therapeutic effectiveness and extend treatment possibilities for neurological disorders. These bioequivalent tablets represent generic medications, designed to deliver an identical dose of the active ingredient into the bloodstream with the same speed and efficiency as their branded counterparts, thereby assuring similar safety profiles and therapeutic effects. An illustration of this trend occurred in March 2024, when Strides Pharma Science Limited, an India-based pharmaceutical company, introduced Gabapentin Tablets USP in 600 mg and 800 mg strengths. This launch followed approval from the United States Food & Drug Administration (USFDA) and aimed to broaden its neurology portfolio within the US market. This innovative gabapentin formulation offers enhanced bioavailability, precise dosing, and patient-friendly administration. These attributes contribute to more consistent therapeutic outcomes, better symptom control, and increased convenience for patients requiring long-term therapy. Specifically, Gabapentin tablets USP, 600 mg, demonstrate versatile therapeutic potential, enabling effective management for various neurological conditions, including neuropathic pain and partial seizures, by virtue of its reliable dosing and established clinical efficacy.

Which Leading Companies Dominate The Gabapentin Market Share?

Major companies operating in the gabapentin market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan Inc., Apotex Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., Ipca Laboratories Private Limited, Granules India Limited, Medley Pharmaceuticals Limited, Wockhardt Limited, Epic Pharma LLC, Healing Pharma India Pvt. Ltd., Rochem International Inc., Accord Healthcare Limited, Strides Pharma Science Limited, Ascend Laboratories LLC

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/gabapentin-global-market-report

How Does The Gabapentin Market Perform Across Major Global Regions?

North America was the largest region in the gabapentin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gabapentin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Gabapentin Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24544&type=smp

Browse Through More Reports Similar to the Global Gabapentin Market 2026, By The Business Research Company

Glycomic Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/glycomic-therapeutics-global-market-report

Glycopeptide Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report

Antiglaucoma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795